Antibody Peptide Based Antifungal Immunotherapy

We addressed the possibility that any fragment of the variable and constant regions may display antifungal (fungicidal and/or immunomodulatory) activity irrespective of the specificity for a given antigen or the isotype of the belonging antibody (Ab). Complementarity determining regions (CDRs)-based...

Full description

Bibliographic Details
Main Authors: Walter eMagliani, Stefania eConti, Laura eGiovati, Pier Paolo eZanello, Martina eSperindè, Tecla eCiociola, Luciano ePolonelli
Format: Article
Language:English
Published: Frontiers Media S.A. 2012-06-01
Series:Frontiers in Microbiology
Subjects:
Online Access:http://journal.frontiersin.org/Journal/10.3389/fmicb.2012.00190/full
id doaj-ff085c52d4214eeb9dbaca649436fe5e
record_format Article
spelling doaj-ff085c52d4214eeb9dbaca649436fe5e2020-11-24T22:57:46ZengFrontiers Media S.A.Frontiers in Microbiology1664-302X2012-06-01310.3389/fmicb.2012.0019028213Antibody Peptide Based Antifungal ImmunotherapyWalter eMagliani0Stefania eConti1Laura eGiovati2Pier Paolo eZanello3Martina eSperindè4Tecla eCiociola5Luciano ePolonelli6University of Parma - ItalyUniversity of Parma - ItalyUniversity of Parma - ItalyUniversity of Parma - ItalyUniversity of Parma - ItalyUniversity of Parma - ItalyUniversity of Parma - ItalyWe addressed the possibility that any fragment of the variable and constant regions may display antifungal (fungicidal and/or immunomodulatory) activity irrespective of the specificity for a given antigen or the isotype of the belonging antibody (Ab). Complementarity determining regions (CDRs)-based synthetic peptides of recombinant and monoclonal murine and human Abs directed to unrelated epitopes showed differential in vitro and/or in vivo antifungal activities, conceivably mediated by different mechanisms of action. Alanine substituted peptides obtained from fungicidal CDR sequences, and used as surrogates of natural point mutations, showed further differential increased, unaltered or decreased candidacidal activitiy. Candidacidal CDR-related peptides, which proved to be devoid of cytotoxicity on mammalian cells, showed to be characterized in solution by a peculiar self-aggregation-releasing property that could provide protection against proteases and a slow release of the active form over time. An immunomodulatory synthetic peptide related to a CDR proved to exert a therapeutic effect against systemic candidiasis without possessing direct candidacidal properties. Likewise CDR-related peptides, synthetic peptides with sequence identical to fragments putatively deriving from the cleavage of the constant region of Abs proved to display in vitro and/or in vivo fungicidal and/or immunomodulatory antifungal activity. These results open a new scenario about the possibility that Ab fragments may effectively influence the antifungal immune response in a way reminiscent of peptides of innate immunity. It is suggested, moreover, that immunoglobulins (Igs) may be sources of an unlimited number of sequences potentially active against fungal agents and related mycoses.http://journal.frontiersin.org/Journal/10.3389/fmicb.2012.00190/fullAntifungal antibodiesKiller toxinAntibiobodiesSynthetic CDRsKiller peptidesAntifungal peptides
collection DOAJ
language English
format Article
sources DOAJ
author Walter eMagliani
Stefania eConti
Laura eGiovati
Pier Paolo eZanello
Martina eSperindè
Tecla eCiociola
Luciano ePolonelli
spellingShingle Walter eMagliani
Stefania eConti
Laura eGiovati
Pier Paolo eZanello
Martina eSperindè
Tecla eCiociola
Luciano ePolonelli
Antibody Peptide Based Antifungal Immunotherapy
Frontiers in Microbiology
Antifungal antibodies
Killer toxin
Antibiobodies
Synthetic CDRs
Killer peptides
Antifungal peptides
author_facet Walter eMagliani
Stefania eConti
Laura eGiovati
Pier Paolo eZanello
Martina eSperindè
Tecla eCiociola
Luciano ePolonelli
author_sort Walter eMagliani
title Antibody Peptide Based Antifungal Immunotherapy
title_short Antibody Peptide Based Antifungal Immunotherapy
title_full Antibody Peptide Based Antifungal Immunotherapy
title_fullStr Antibody Peptide Based Antifungal Immunotherapy
title_full_unstemmed Antibody Peptide Based Antifungal Immunotherapy
title_sort antibody peptide based antifungal immunotherapy
publisher Frontiers Media S.A.
series Frontiers in Microbiology
issn 1664-302X
publishDate 2012-06-01
description We addressed the possibility that any fragment of the variable and constant regions may display antifungal (fungicidal and/or immunomodulatory) activity irrespective of the specificity for a given antigen or the isotype of the belonging antibody (Ab). Complementarity determining regions (CDRs)-based synthetic peptides of recombinant and monoclonal murine and human Abs directed to unrelated epitopes showed differential in vitro and/or in vivo antifungal activities, conceivably mediated by different mechanisms of action. Alanine substituted peptides obtained from fungicidal CDR sequences, and used as surrogates of natural point mutations, showed further differential increased, unaltered or decreased candidacidal activitiy. Candidacidal CDR-related peptides, which proved to be devoid of cytotoxicity on mammalian cells, showed to be characterized in solution by a peculiar self-aggregation-releasing property that could provide protection against proteases and a slow release of the active form over time. An immunomodulatory synthetic peptide related to a CDR proved to exert a therapeutic effect against systemic candidiasis without possessing direct candidacidal properties. Likewise CDR-related peptides, synthetic peptides with sequence identical to fragments putatively deriving from the cleavage of the constant region of Abs proved to display in vitro and/or in vivo fungicidal and/or immunomodulatory antifungal activity. These results open a new scenario about the possibility that Ab fragments may effectively influence the antifungal immune response in a way reminiscent of peptides of innate immunity. It is suggested, moreover, that immunoglobulins (Igs) may be sources of an unlimited number of sequences potentially active against fungal agents and related mycoses.
topic Antifungal antibodies
Killer toxin
Antibiobodies
Synthetic CDRs
Killer peptides
Antifungal peptides
url http://journal.frontiersin.org/Journal/10.3389/fmicb.2012.00190/full
work_keys_str_mv AT walteremagliani antibodypeptidebasedantifungalimmunotherapy
AT stefaniaeconti antibodypeptidebasedantifungalimmunotherapy
AT lauraegiovati antibodypeptidebasedantifungalimmunotherapy
AT pierpaoloezanello antibodypeptidebasedantifungalimmunotherapy
AT martinaesperinde antibodypeptidebasedantifungalimmunotherapy
AT teclaeciociola antibodypeptidebasedantifungalimmunotherapy
AT lucianoepolonelli antibodypeptidebasedantifungalimmunotherapy
_version_ 1725649303692640256